Everbright Securities: Maintains "Buy" rating on Keymed Biosciences-B (02162.HK), rapid commercialization ramp-up

Zhitong Finance APP has learned that Everbright Securities issued a research report stating that, considering the rapid sales growth of Keymed Biosciences-B's (02162.HK) core product Kangyueda in 26H1 and the considerable one-off gains brought by the overseas licensing transaction for CM336, the bank has raised its 2026 forecast for net profit attributable to shareholders to RMB 910 million; considering the company's comprehensive acceleration of its R&D pipeline and continuously accelerating commercialization, the bank has raised its 2027 forecast for net profit attributable to shareholders to RMB 46 million, and added a 2028 forecast for net profit attributable to shareholders of RMB 461 million. As the commercialization of the company's core products enters a period of rapid volume expansion, overseas BD continues to validate the value of its R&D platform, and the subsequent pipeline echelon builds up strength for future breakout, the "Buy" rating is maintained.